Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data
IntroductionMolecular targeted therapies, including advanced atopic dermatitis (AD) treatment with Janus kinase 1 inhibitors (JAK1i) and anti-interleukin-13 antibodies (IL-13Ab), are emerging as effective options. However, the predictive biomarkers for treatment responses remain unclear. Therefore,...
Saved in:
| Main Authors: | Emi Sato, Naoko Obonai, Mayuko Iwata, Kotaro Ito, Shinichi Imafuku |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639932/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interleukin-31: A Pro-inflammatory Oriented Cytokine
by: Giuseppe Murdaca, et al.
Published: (2025-06-01) -
Immune response in atopic dermatitis: main pathogenetic mechanisms and stage-dependent correlations with age in regard to dermatological and non-dermatological systemic processes
by: M. B. Drozhdina, et al.
Published: (2021-05-01) -
Pathogenetic role of IL-4 and IL-13 in atopic dermatitis: The inhibitory pathways
by: D. Sh. Macharadze
Published: (2025-03-01) -
Real‐life retrospective multicentre study to describe the use of dupilumab in paediatric patients with atopic dermatitis in Spain: Patient profile, effectiveness and safety
by: Eulalia Baselga Torres, et al.
Published: (2025-06-01) -
Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study
by: Lingyu Hu, et al.
Published: (2023-07-01)